Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for preventing and treating urinary incontinence

A treatment method, a technology for urinary incontinence, applied in chemical instruments and methods, pharmaceutical formulations, urinary system diseases, etc., and can solve problems such as no reported 100% success.

Inactive Publication Date: 2020-02-11
NOVARTIS AG
View PDF85 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Valrlev et al. point out that despite the fact that more than 90 drugs have been declared effective in the treatment of urinary incontinence, although there are a large number of drugs, 100% success (eg, complete restoration of the ability to effectively control the bladder (according to patients with bladder disease) has not been reported. Perception of situation (PPBC), such as absence of sudden strong urgency or episodes of nocturia)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for preventing and treating urinary incontinence
  • Methods for preventing and treating urinary incontinence
  • Methods for preventing and treating urinary incontinence

Examples

Experimental program
Comparison scheme
Effect test

example

[0451] general method

[0452] ActRIIB antibodies, their characterization and methods related thereto have been disclosed in WO 2010 / 125003, such as (i) functional assays, (ii) reporter gene assay (RGA), (iii) culture of HEK293T / 17 cell line, (iv) Myostatin-induced luciferase reporter gene assay, (v) specificity ELISA, (vi) ActRIIB / Fc-myostatin binding interaction ELISA, (vii) FACS titration of hActRIIB-expressing and hActRIIA-expressing cells , (viii) binding to primary human skeletal muscle cells, (ix) affinity determination for selected anti-human ActRIIB Fabs using surface plasmon resonance (Biacore), (x) CK assay, (xi) animal model, ( xii) treatment regimen, (xiii) statistical analysis, (xiii) panning, (xv) antibody identification and characterization, (xvi) optimization of antibodies derived from first affinity matured, (xvii) IgG2 conversion of affinity matured Fab (1st maturation), (xviii) second affinity maturation, (xx) IgG2 conversion and characterization of IgG2 (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure relates to novel uses and methods for preventing and / or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRIIreceptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.

Description

technical field [0001] This disclosure relates to the field of activin receptor type II (ActRII) antagonists, such as those capable of antagonizing activin, growth differentiation factor (GDF), bone morphogenetic protein (BMP) and A molecule that binds myostatin to the human ActRII receptor, such as an antagonist antibody against ActRIIA and / or ActRIIB, such as bimagrumab. In particular, the present invention relates to the treatment and prevention of urinary incontinence by administering to a subject a therapeutically effective amount of an ActRII receptor antagonist. Background technique [0002] Activin receptor type IIB (ActRIIB) is a signaling receptor for individual members of the transforming growth factor beta (TGF-beta) superfamily. Members of this family include activin A, nodal, BMP2, BMP6, BMP7, BMP9, GDF5, GDF8 (myostatin) and GDF11, all of which are involved in the negative regulation of muscle (Akpan et al., 2009). [0003] Myostatin (GDF8) acts through acti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P21/00A61P13/00
CPCC07K16/2863C07K2317/21C07K2317/34C07K2317/76A61P13/00A61P21/00A61K38/00C07K2317/565C07K14/495C07K16/28
Inventor 畠山慎二M·克奈塞尔E·特里费里夫
Owner NOVARTIS AG